451 related articles for article (PubMed ID: 8630957)
21. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
[TBL] [Abstract][Full Text] [Related]
22. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
23. [Expression and significance of hTERT mRNA in breast carcinoma and its relation to p53].
Tang F; Gu DH; Wang H; Zhu TF; Zhu HG; Xu ZD; Hu XQ
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):192-5. PubMed ID: 16875603
[TBL] [Abstract][Full Text] [Related]
24. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
[TBL] [Abstract][Full Text] [Related]
25. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
26. Oestrogen receptor expression in the normal and pre-cancerous breast.
Shoker BS; Jarvis C; Sibson DR; Walker C; Sloane JP
J Pathol; 1999 Jul; 188(3):237-44. PubMed ID: 10419589
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
28. Timing of critical genetic changes in human breast disease.
Ellsworth RE; Ellsworth DL; Deyarmin B; Hoffman LR; Love B; Hooke JA; Shriver CD
Ann Surg Oncol; 2005 Dec; 12(12):1054-60. PubMed ID: 16228814
[TBL] [Abstract][Full Text] [Related]
29. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
Krajewski S; Thor AD; Edgerton SM; Moore DH; Krajewska M; Reed JC
Clin Cancer Res; 1997 Feb; 3(2):199-208. PubMed ID: 9815673
[TBL] [Abstract][Full Text] [Related]
30. Atypical ductal hyperplasia in breast core needle biopsies. Correlation of size of the lesion, complete removal of the lesion, and the incidence of carcinoma in follow-up biopsies.
Renshaw AA; Cartagena N; Schenkman RH; Derhagopian RP; Gould EW
Am J Clin Pathol; 2001 Jul; 116(1):92-6. PubMed ID: 11447758
[TBL] [Abstract][Full Text] [Related]
31. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
[TBL] [Abstract][Full Text] [Related]
32. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of HSP90 in the continuum of breast ductal and lobular lesions.
Zagouri F; Sergentanis TN; Provatopoulou X; Kalogera E; Chrysikos D; Lymperi M; Papadimitriou CA; Zografos E; Bletsa G; Kalles VS; Zografos GC; Gounaris A
In Vivo; 2011; 25(4):669-72. PubMed ID: 21709012
[TBL] [Abstract][Full Text] [Related]
35. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
Elayat G; Selim AG; Wells CA
Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
[TBL] [Abstract][Full Text] [Related]
36. Expression of scatter factor and c-met receptor in benign and malignant breast tissue.
Jin L; Fuchs A; Schnitt SJ; Yao Y; Joseph A; Lamszus K; Park M; Goldberg ID; Rosen EM
Cancer; 1997 Feb; 79(4):749-60. PubMed ID: 9024713
[TBL] [Abstract][Full Text] [Related]
37. Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM; Ostrowski JL; Harkins L; Rice AJ; Loney DP
Histopathology; 1998 Dec; 33(6):531-6. PubMed ID: 9870147
[TBL] [Abstract][Full Text] [Related]
38. Genetic mutations and expression of p53 in non-invasive breast lesions.
Mao X; Fan C; Wei J; Yao F; Jin F
Mol Med Rep; 2010; 3(6):929-34. PubMed ID: 21472335
[TBL] [Abstract][Full Text] [Related]
39. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics.
Visscher DW; Wallis TL; Crissman JD
Cancer; 1996 Jan; 77(2):315-20. PubMed ID: 8625240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
